

**DBEI CCEB Epidemiology Seminar Series 2025-2026 - 5/14/2025 | Meredith Matone, DrPH, MHS |
Advancing a Multi-Method Community-Engaged Research Portfolio: A Case Study in Maternal and Infant
Home Visiting in Pennsylvania
May 14, 2025
9:00 AM - 10:00 AM**

Target Audience

This program has been designed for ALL SPECIALTIES

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss appropriate targets for intervention to improve public health.
- 2 Discuss statistical techniques for specific applications of epidemiological research and understand their limitations and assumptions.
- 3 Describe the role of epidemiological studies to inform clinical practice in veterinary and human medicine.

Session Educational Objectives

After completing this educational activity, participants should be able to:

- 1 Review the community-engaged research continuum.
- 1 Describe the progression from observational research to community-engaged co-learning and pilot design.
- 2 Describe the use of quasi-experimental designs in effectiveness evaluation of public health programs following scale-up.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is not approved for nursing contact hours

Pharmacists: This activity is approved for **1.00** contact hours

UAN Number: JA0000324-0000-25-017-L04-P

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

Acknowledgement of Commercial Support*

None

For more information, please contact
Mae Phelps, Alexa Pecunies
(309) 706-8926, (267) 835-0045

emae@upenn.edu, alexa.pecunies@pennmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

| Name of individual | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|------------------------------|---------------------------------|---|
| Michael Z David, MD, MS, PhD | Co-Director | Consulting Fee-Glaxo Smith Kline (Relationship has ended) Grant or research support-Glaxo Smith Kline (Relationship has ended) Consulting Fee-Johnson & Johnson (Relationship has ended) Grant or research support-Contrafect (Relationship has ended) - 09/23/2024 |
| Alexis Ogdie, MD, MSPH | Other Planning Committee Member | Consulting Fee-Pfizer, Inc. Grant or research support-Janssen Pharmaceuticals (J&J) Consulting Fee-CorEvitas Grant or research support-AbbVie, Inc. Grant or research support-Novartis / Amgen Grant or research support-Pfizer, Inc. Consulting Fee-Janssen Pharmaceuticals (J&J) Consulting Fee-Glaxo Smith Kline Consulting Fee-UCB Consulting Fee-Bristol-Myers Squibb Consulting Fee-Novartis / Amgen Consulting Fee-AbbVie, Inc. Consulting Fee-Takeda Pharmaceuticals - 10/25/2024 |
| Ricardo Castillo-Neyra, DVM | Co-Director | Nothing to disclose - 09/20/2024 |
| Sean Hennessy, PharmD | Pharmacy Planner | Consulting Fee-Covis Pharma GmbH (Relationship has ended) Consulting Fee-Urovant Sciences (Relationship has ended) Consulting Fee-Astra Zeneca Pharmaceuticals Consulting Fee-Novo |

| | | |
|-----------------------|-------------|---|
| | | Nordisk Consulting Fee-Glaxo Smith Kline Consulting Fee-Eli Lilly Consulting Fee-Provention Bio, Inc (Relationship has ended) Consulting Fee-Bluebird Bio, Inc (Relationship has ended) Consulting Fee-Amylyx Pharmaceuticals Inc (Relationship has ended) Consulting Fee-Ipsen (Relationship has ended) Consulting Fee-i2o (Relationship has ended) Consulting Fee-Balance Ophthalmics (Relationship has ended) Consulting Fee-Lykos Therapeutics (Relationship has ended) Consulting Fee-Applied Therapeutics Inc (Relationship has ended) - 09/17/2024 |
| Meredith Matone, DrPH | Faculty | Nothing to disclose - 10/18/2024 |
| Ellen C Caniglia | Co-Director | Nothing to disclose - 09/17/2024 |

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected